Company ProfilePremium

Quest for Growth Belgium

Company Profile Analysis

Ticker: QFG.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
Quest for Growth Belgium - Company showcase

Year Founded & Workforce

1998

Quest for Growth Belgium logo

Quest for Growth Belgium Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Quest for Growth Belgium Overview

Quest for Growth is one of Belgium's few listed private-equity-style vehicles open to retail investors. As a public privak it offers daily-tradable, tax-efficient exposure to three segments: European listed small- and mid-caps (≈59% of NAV at mid-2026), venture and growth funds largely managed by Capricorn Partners (≈31%), and direct venture/growth investments (≈9%), across three themes — digital, healthtech and cleantech. After a difficult 2022–2025 period in venture valuations, the fund announced a strategic reorientation in late 2025 back to its founding mission, trimming large-cap listed positions and returning EUR 1 per share (EUR 18.7M) via a capital reduction in March 2026. Co-founder Jos Peeters became reference shareholder in 2025 after buying Belfius Insurance's stake. The shares trade at a historically wide discount of around 50% to NAV, versus a ten-year average near 27%.


Company's own description

In its NAV releases, Quest for Growth describes its diversified portfolio as mostly invested in growth companies listed on European stock exchanges, in venture and growth capital, and in venture and growth funds, focusing on innovative companies. Its 2026 investor material lists the investment case as diversified segments, diversified themes (cleantech, healthtech, digitalisation), daily tradability, favourable public-privak tax status, and a significant discount to NAV (analyst presentation, 31 Jul 2026).

Business model and "revenue" model

Income lineFY2023 (EUR Mn)FY2024 (EUR Mn)FY2025 (EUR Mn)
Net realised gains/(losses) on financial assets-6.19-5.774.00
Net unrealised gains/(losses)2.48-0.28-6.26
Dividend income1.822.162.14
Net interest income0.080.140.05
Total income from investments-1.80-3.75-0.08

QFG earns returns, not sales. Its income consists of:

(FY2025 annual results press release.) Costs are dominated by a flat management fee to Capricorn Partners (EUR 1.48M p.a. in 2023–2025). There is no product, subscription or licensing revenue.

Value-chain position, customers, end-markets

QFG is a capital provider: (i) a minority portfolio investor in listed European small/mid-caps; (ii) a limited partner in Capricorn-managed funds (and selectively third-party funds such as Fortino Ventures III); (iii) a co-investor alongside those funds in direct venture rounds. Its "customers" are its shareholders — largely Belgian retail investors seeking tax-efficient access to private markets. End-markets of portfolio companies: industrial technology, healthcare/medtech, software/AI, cleantech and sustainable chemistry.

Independent characterisation

QFG is a sub-scale (≈EUR 110M NAV) closed-end fund whose fixed management fee (~1.4–1.5% of NAV) and persistent discount have weighed on shareholder returns: the ten-year share holding-period return to 30 Jun 2026 was −20.4%, versus +13.9% for NAV (analyst presentation). Its strongest asset is a disciplined listed-equity book with long-term winners (Nexus, Melexis, Wolters Kluwer); its weakest is a venture/fund book heavily exposed to cleantech and SaaS valuations, which has been marked down repeatedly. The late-2025 capital return and reorientation are a direct response to the discount problem.

Strategy

Stated themes (FY2025 release; HY 2026 presentation): return to the original mission of giving every shareholder tax-efficient, tradable access to diversified unlisted growth companies (directly and via funds) plus successful listed small/mid-caps; three segments; three themes (cleantech, healthtech, digitalisation).

No numerical medium-term targets or NAV/dividend guidance are published. Dividend policy: no dividend for FY2025 given the loss and carried-forward losses.

Products & Services

Quoted equities (known positions, 2025–2026)

CompanyCountryDescriptionStatus / data
NedapNLTechnology (healthcare, livestock, retail, security; software ≈40% of revenue)Held; +72% in 2025
NorbitNOSonar (Oceans), road-toll systems, industrial electronicsAdded Apr 2025; ~+55%
Beijer AlmaSEIndustrial springs (Lesjöfors)Added 2025; +51%
AndritzATIndustrial equipmentHeld; +43% in 2025
Jensen-GroupBEIndustrial laundry equipmentHeld; +39% in 2025
INITDEPublic-transport softwareHeld; +30% in 2025
ArcadisNLInfrastructure consultancyAdded 2025 (small); −26%
De'LonghiITCoffee machinesAdded 2025
Mensch und MaschineDECAD/CAM softwareAdded 2025 (small)
Schott PharmaDEDrug containment/delivery (syringes, cartridges, vials); market cap ~EUR 2.6BNew 2026 (top-10)
SP GroupDKCustom polymer parts for healthcare/cleantech/industry; ~EUR 640MNew 2026
KronesDEBeverage filling/packaging; ~EUR 4.3BNew 2026
Kerry GroupIEFood ingredients (~EUR 13B; 2nd largest position)Exited H1 2026
MelexisBEAutomotive semiconductorsExited H1 2026 (+1,300% since 2011)
Wolters Kluwer, Roche, Nexus, Financière de Tubize, Datron, ABO EnergyVarious—Exited 2025

Direct venture & growth capital

CompanyCountrySectorLatest activity
GradyentNLAI for district heating/energy networksEUR 1.5M in EUR 28M round (2025), led by Blue Earth Capital
EclecticIQNLCyber threat intelligenceInternal rounds 2025 and EUR 100k in EUR 1.75M round (2026)
DMC BiotechnologiesUSBiomanufacturingUSD 110k in USD 7.8M round (Apr 2026)
fruitcore roboticsDEIndustrial roboticsEUR 75k in EUR 2.85M internal round (Q1 2026)
Rein4cedBEComposite bike framesBankrupt end-2025
Others——Not individually retrieved

Undisclosed valuation changes in V&G capital: −1.4% of segment (H1 2026 presentation).

Venture & growth funds (share of NAV at 30 Jun 2026 where shown)

FundThemeCommitment / activityNotable underlying
Capricorn Digital Growth FundDigitalCalls EUR 3.5M (2025), EUR 2.4M (H1 2026)Azumuta, Conxai (EUR 2.0M), Rocsys (EUR 3.5M), Gradyent, EclecticIQ
Capricorn Healthtech Fund IIHealthCommitment raised from EUR 12.5M to EUR 15M (2025); calls EUR 0.8M (2025), EUR 2.5M (H1 2026); fund size EUR 62M → EUR 89MAspect Analytics, Xyall (EUR 3.0M), Oska Health (EUR 2.0M), EndoTools (EUR 5.0M, Q3 2026)
Capricorn Healthtech Fund (I)HealthLegacy—
Capricorn SCF (Sustainable Chemistry)CleantechCalls EUR 0.6M (2025), EUR 0.8M (H1 2026)DMC, Zeopore, Econic, Rein4ced
Capricorn Fusion China FundDiversifiedCalls EUR 0.2M (2025 and H1 2026)Spectricity, fruitcore robotics
Capricorn ICT ArkivDigitalDistribution EUR 2.0M (H1 2026, of which EUR 0.5M dividend)Icometrix (sold to GE Healthcare)
Fortino Ventures IIIB2B SaaS/AIEUR 2M committed May 2026; EUR 0.2M calledmkind, Polysense.ai, Birdsview.com
Life Sciences Partners IVLife sciencesFinal EUR 0.5M distribution Dec 2025Fully realised

Financial Narrative

Currency EUR. For an investment fund, "revenue" = total income from investments; "operating income" = profit from operating activities. EBITDA, gross profit, capex and cash conversion cycle are not meaningful.

Income statement

Sources: FY2022 release (FY2021–22), FY2025 release (FY2023–25), Annual Report 2025 (dividend history). FY2025 ROE uses NAV adjusted to add back the EUR 18.73M capital-repayment liability. Margins (gross/operating/net) are not meaningful because income is negative or near zero in FY2023–FY2025. "Revenue CAGR" not meaningful.

Commentary. FY2021 was the last strong year (+21.9% ROE). Since then, rising rates crushed growth valuations (2022), and venture/fund marks deteriorated each year from 2023 to 2025. The listed book has been the stabiliser (+18% gross in 2025, in line with STOXX Europe Small 200), but the fixed fee (~EUR 1.5M) consumes most dividend income, so positive NAV returns depend on capital gains.

Balance sheet

FY2025 "other liabilities" includes the EUR 18,733,961 capital distribution payable; NAV per share 7.05 adds this back (unadjusted equity/share ≈ EUR 6.05). QFG is debt-free.

Cash flow and capital returns

FY2021 dividend total EUR 19.05M (ordinary EUR 17.08M + preference EUR 1.97M), paid April 2022 (Annual Report 2025 key figures). Capital reduction decided Dec 2025, paid 23 Mar 2026. Operating cash flow and capex in the classic sense not applicable.

Monthly NAV and price, 2026 (NAV press releases)

Discrepancy note: March NAV appears as EUR 5.51 (April release) and EUR 5.50 (later tables); March discount appears as 48.2% and 48.3% in different tables. The drop from February to March reflects the EUR 1 capital repayment (ex-date ~19–23 Mar 2026) plus the Q1 software sell-off.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsThemes

Quoted equities

European listed small/mid-caps (some larger caps being reduced)

Industrial tech, healthcare, digital

Venture & growth capital (direct)

Minority stakes, mostly co-investments with Capricorn funds

Digital, health, cleantech

Venture & growth funds

LP commitments: Capricorn Digital Growth Fund, Capricorn Healthtech Fund (I & II), Capricorn SCF, Capricorn Fusion China Fund, Capricorn ICT Arkiv, Fortino Ventures III, others

Digital, health, cleantech, diversified

Segment income (EUR Mn)

Segment income (EUR Mn)FY2023FY2024FY2025

Quoted equities

5.382.5612.64

Venture & growth capital (direct)

-1.82-3.54-3.95

Venture & growth funds

-5.44-2.91-8.81

Total income from investments

-1.80-3.75-0.08

Revenue by Segment (%) and Segment Margins & Growth (%)

Segment (% of portfolio)31 Dec 202530 Jun 2026

Quoted equities

57.758.7

Venture & growth capital

8.08.7

Venture & growth funds

23.931.3

Cash and other net assets

10.31.3

Dividends & Capital Returns and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total income from investments (EUR Mn)

——-1.80-3.75-0.08

Dividend income (EUR Mn)

——1.822.162.14

Total operating expenses (EUR Mn)

——-2.24-1.98-2.04

of which management fee (EUR Mn)

——-1.48-1.48-1.48

Profit from operating activities (EUR Mn)

——-3.18-5.89-2.06

Pre-tax result (EUR Mn)

——-3.18-5.89-2.06

Net result (EUR Mn)

33.14-24.83-3.52-6.34-2.42

EPS basic = diluted (EUR)

1.98-1.40-0.19-0.34-0.13

Gross dividend per ordinary share for the year (EUR)

1.020000

Return on equity (%)

21.87-14.70-2.44-4.50-1.80

Key Financials and Margin Analysis (%)

MetricH1 2025H1 2026

Net result (EUR Mn)

3.8-3.4

Q2 result (EUR Mn)

—6.9

Return on NAV (%)

2.83-2.3

NAV per share, period end (EUR)

—5.86

Share price, period end (EUR)

4.042.99

Discount (%)

45.249.0

Balance Sheet and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (EUR Mn)

——140.78134.46132.04

Cash and equivalents (EUR Mn)

——6.803.3812.83

Financial assets at FVTPL — equity (EUR Mn)

——132.80130.24118.24

Total debt (EUR Mn)

00000

Net debt (EUR Mn)

——-6.80-3.38-12.83

Equity attributable to shareholders (EUR Mn)

——140.74134.41113.25

Other liabilities (EUR Mn)

——0.040.0518.79

Goodwill and intangibles (EUR Mn)

00000

NAV per share (EUR)

10.717.93—7.177.05

Average shares outstanding (M)

——17.7718.6018.73

Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025

Dividends declared for year (EUR Mn)

19.050000

Capital returned via reduction (EUR Mn)

000018.73

Buybacks (EUR Mn)

00000

Margin Analysis (%)

RatioFY2024FY2025

ROE (%)

-4.50-1.80

ROA (net result / avg assets) (%)

-4.6-1.8

Operating expense ratio (opex / avg NAV) (%)

1.41.5

Management fee / avg NAV (%)

1.11.1

Debt/equity (x)

00

Financial Analysis

MetricFeb26Mar26Apr26May26Jun26Jul26Aug26Sep26

NAV per share (EUR)

6.985.515.825.965.865.966.045.82

Share price (EUR)

4.422.852.953.002.992.973.032.79

Discount (%)

36.648.249.349.749.050.149.852.1

Share Price and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Year-end share price (EUR)

7.986.00—3.984.19

NAV per share (EUR)

10.717.93—7.177.05

Discount (%)

25.524.3—44.540.5

Gross dividend per share (EUR)

1.020000

Analyst Conclusions

Guidance: none quantitative. Management highlights attractive small-cap valuations, cautious optimism on venture in 2026, and the discount as an entry opportunity.

Bull case

  1. A ~52% discount means the market values the listed book alone (~59% of NAV ≈ EUR 64M) above the entire market cap (~EUR 52M) — the unlisted book is effectively free.

  2. Rotation into low-P/E industrial quality names (Krones 10.3x, SP Group 11.4x) plus small-cap mean reversion could drive NAV growth.

  3. Exits from Capricorn funds (Icometrix precedent) and recovering software multiples could reverse venture write-downs.

Bear case

  1. Four straight loss years and fixed fees leave little margin for error.

  2. Venture/cleantech exposure keeps producing write-downs and failures.

  3. Without buybacks or further distributions, the discount may stay structurally wide.

Catalysts (12 months): monthly NAVs; FY2026 results (late Jan 2027); details and effect of the new remuneration policy; any buyback/distribution decision; fund exits; small-cap market direction.

Analyst verdict. Quest for Growth offers something rare in Belgium — a listed, tax-efficient route into venture and growth capital combined with a well-run small/mid-cap equity book. Its record in listed stocks is genuinely strong, with multi-bagger holdings such as Nexus and Melexis. The problem has been everything around that core: venture and cleantech fund marks have deteriorated for several years, the fixed management fee absorbs most dividend income, and the discount to NAV has roughly doubled from its historical norm, leaving long-term shareholders with negative ten-year returns even as NAV grew modestly.

The late-2025 reorientation, the EUR 1 per share capital return, the arrival of a co-founder as reference shareholder and a slimmer board show that governance is responding. But the H1 2026 numbers illustrate the fragility: a single quarter of software-multiple compression erased the 2025 listed gains, and the discount widened further to 52% by September 2026.

At around 0.48x NAV, the shares price in substantial pessimism — the quoted portfolio alone exceeds the market capitalisation. For a patient investor, that is a margin of safety. Yet discounts on small closed-end funds can persist for years without a catalyst. We would want to see concrete discount-control measures (buybacks, regular distributions, or fee alignment under the new policy) and stabilisation of venture valuations before turning positive.

Our stance: speculative value. The most important monitorables are the terms of the new remuneration policy, any capital-return decisions at the FY2026 results, and whether Capricorn fund exits begin to crystallise value above carrying marks.


Sources: QFG annual results 2025 press release (29 Jan 2026); Annual Report 2025 (NL/FR); AGM 2025 and 2026 proxies; semi-annual reports 30 Jun 2025 and 30 Jun 2026; press & analyst meeting 31 Jul 2026; monthly NAV releases (Apr–Oct 2026); FY2022 annual results release; shareholder-structure and team pages (capricorn.be); Parqet (secondary, flagged).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleNotes

Lieve Creten

Chair

Independent status not confirmed in documents reviewed

Sabine Vermassen

Director; Executive Officer

Managing Partner, Capricorn Partners

Jos B. Peeters

Director (nominated by preference shareholders per 2026 proxy)

Co-founder; reference shareholder (≈12.8%)

Thierry François

Director

Joined 2026, replacing Philippe de Vicq and Jos Clijsters

Véronique Léonard

Director

—

Paul Van Dun

Director

—

Executive Leadership Team

NameRole

Steven Levecke

Executive Officer; Managing Partner; unquoted portfolio

Sabine Vermassen

Executive Officer; Managing Partner

Jan Avonts

Investment Director; quoted portfolio

Jelle Van de Putte

Fund Administrator

Kim De Keyser

Valuation Expert

Major Shareholders

HolderShares%Date

Jos B. Peeters

2,398,238

≈12.8 (derived)

31 Dec 2025

Belfius Insurance

0 (sold)

previously 11.98

Jun 2025

Philippe Haspeslagh

Co-acquirer of Belfius stake; individual stake below threshold (not disclosed)

—2025

Free float

≈87

—

derived

Competitive Landscape

Key Competitors

CompetitorTypeOverlapPositioning vs QFG

Gimv

Listed Belgian investment company

Growth/buyout, health, sustainability

Far larger; direct deals

Sofina

Listed Belgian holding

Growth/VC funds

Far larger; global VC

Brederode

Listed Belgian/Lux holding

PE funds + listed

Larger; fund-of-funds model

Ackermans & van Haaren

Listed Belgian holding

Diversified

Much larger

TINC

Listed Belgian public privak

Same tax status, infrastructure

Comparable legal wrapper, different asset class

Smartfin, Volta Ventures, Inventures

Belgian VC funds

Venture

Unlisted, institutional

PMV / SFPI-FPIM

Public investors

Belgian venture/growth

Co-investors and competitors for deals

Belgian small-cap equity funds (bank-managed)

Mutual funds

Listed small/mid-caps

Daily NAV liquidity, no discount

European listed growth/VC trusts

Listed funds

Venture/growth access

Larger, pan-European

Competitor Detail

BenchmarkQFG FY2025

NAV (EUR Mn, adjusted)

≈132

ROE (%)

-1.8

Discount (%)

40.5

Opex ratio (%)

≈1.5

Company Snapshot

1998

Founded

Leuven, Belgium

Headquarters

SWOT Analysis

Strengths

  • Listed book returned ~18% gross in 2025 and contributed EUR 12.6M segment income.
  • Long-term stock-picking wins: Nexus >1,000% over 13 years; Melexis +1,300% since 2011; Wolters Kluwer >150% (2020–2025).
  • Debt-free balance sheet (total liabilities EUR 0.05M at end-2024).
  • Public-privak tax efficiency and daily tradability.
  • Engaged co-founder reference shareholder (≈12.8%).
  • Demonstrated willingness to return capital (EUR 18.7M in March 2026).

Weaknesses

  • Four consecutive annual losses (2022–2025) and an H1 2026 loss of EUR 3.4M.
  • Ten-year share holding-period return −20.4% to mid-2026.
  • Fixed management fee EUR 1.48M ≈ 69% of FY2025 dividend income.
  • Venture funds lost EUR 8.8M in FY2025 (unrealised −EUR 9.3M).
  • Smaller NAV after capital return reduces cost efficiency.
  • Concentration of fund exposure in vehicles managed by its own manager.

Opportunities

  • Discount ~50–52% vs ten-year average ~27% — re-rating potential.
  • Small-cap valuations below historical averages (Small 200 at 13.4x vs ~16x).
  • Recovery in software multiples after the Q1 2026 sell-off.
  • Exits in Healthtech Fund II and Digital Growth Fund portfolios.
  • Further capital returns or buybacks to close discount.

Threats

  • Further cleantech/SaaS write-downs.
  • Weak venture fundraising environment stresses portfolio companies (e.g. Rein4ced bankruptcy).
  • Uncalled commitments (e.g. Healthtech Fund II EUR 15M, Fortino EUR 2M) drawing on reduced cash.
  • Discount widening further (52.1% in Sep 2026).
  • Equity market correction hitting the 59% listed allocation.
  • Regulatory change to privak tax regime.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Norbit added to portfolioBecame a top performer
Jun 2025Belfius announces sale of 11.98% stakeShareholder change
End Jun 2025Agreement with co-founders Peeters & HaspeslaghNew reference shareholder
30 Jul 2025Transparency notification (Peeters)Filing
31 Jul 2025H1 2025: profit EUR 3.8M; ROE +2.83%Interim
2025Gradyent EUR 28M roundVenture
2025Icometrix sold to GE HealthcareRealisation
2025Healthtech Fund II commitment raised to EUR 15MAllocation
Dec 2025Rein4ced bankruptcyWrite-off
Dec 2025LSP IV final distribution EUR 0.5MRealisation
29 Dec 2025EGM approves EUR 1/share capital reductionCapital return
8 Jan 2026Preliminary NAV EUR 7.09Later cut to 7.05
29 Jan 2026FY2025 results; no dividendResults
30 Jan 2026Press & analyst meetingIR
Q1 2026Software multiple compression ("SaaSpocalypse")Valuation hit
Q1 2026Krones addedRotation
23 Mar 2026EUR 1/share paidCapital return
26 Mar 2026AGM: new remuneration policy; board changesGovernance
9 Apr 2026NAV EUR 5.51; discount 48.3%Discount widens
Apr 2026DMC roundVenture
May 2026Fortino Ventures III EUR 2MNew fund
4 Jun 2026NAV EUR 5.96Recovery
H1 2026Kerry, Melexis sold; SP Group, Schott Pharma addedRotation
9 Jul 2026NAV EUR 5.86—
30 Jul 2026H1 2026 report: loss EUR 3.4MInterim
31 Jul 2026Analyst meetingIR
Q3 2026Healthtech Fund II invests EUR 5M in EndoToolsIndirect
3 Sep 2026NAV EUR 6.04—
8 Oct 2026NAV EUR 5.82; price EUR 2.79; discount 52.1%Widest in data reviewed

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Segment (%): Quoted equities rose from 57.7% in 31 Dec 2025 to 58.7% in 30 Jun 2026.
Quest for Growth Belgium — Revenue by Segment (%)
Series (%)31 Dec 202530 Jun 2026
Quoted equities57.758.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.